Status:
COMPLETED
Cathelicidin LL-37 Levels in the GCF and the Saliva of Smokers and Non-smokers With Stage III,IV Periodontitis
Lead Sponsor:
Cairo University
Conditions:
Smoking Reduction
Eligibility:
All Genders
Brief Summary
Periodontitis is considered an inflammatory disease that results in the disruption of oral hemeostasis and is associated with the presence of dental plaque influenced by genetic and environmental fact...
Detailed Description
Antimicrobial peptides (AMPs) are soluble molecules participating in the innate immunity of mucosal surfaces against pathogens. Dysregulated expression of AMPs has been considered a possible causal me...
Eligibility Criteria
Inclusion
- Presence of a minimum of 15 natural teeth.
- At least four non-adjacent teeth sites in each jaw having CAL ≥ 5 mm and PD \> 5 mm in one or more sites.
- Bleeding on probing (BOP) ≥ 30%.
- Tooth loss due to periodontitis ≤ 4 teeth.
- For smoker's patients; study will include patients who regularly smoked at least 10 cigarettes/day for a minimum of 5 years.
- For non-smokers patients; study will include patients who had never smoked.
Exclusion
- Individuals with a history of systemic diseases or immunological disorders.
- Individuals using hormone replacement therapy.
- Pregnant and lactating women.
- Individuals that received periodontal treatment within the last 6 months.
- Individuals with a history of systemic antibiotics and anti-inflammatory drugs within the last 3 months.
Key Trial Info
Start Date :
February 23 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 15 2021
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04861493
Start Date
February 23 2021
End Date
April 15 2021
Last Update
April 27 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Faculty of dentistry cairo university
Al Manyal, Cairo Governorate, Egypt, 11562